Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2007 by Cytogen Corporation.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Cytogen Corporation
ClinicalTrials.gov Identifier:
NCT00121095
First received: July 13, 2005
Last updated: December 17, 2007
Last verified: December 2007

July 13, 2005
December 17, 2007
July 2005
Not Provided
Primary outcome is safety and tolerability of the combination treatment
Not Provided
Complete list of historical versions of study NCT00121095 on ClinicalTrials.gov Archive Site
Tumor response will be assessed when possible using RECIST criteria.
Not Provided
Not Provided
Not Provided
 
Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer
Phase I/II Trial of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Androgen-Independent Prostate Cancer

The purpose of this study is to investigate the safety, tolerability and anti-tumor effects of treatment with samarium Sm-153 lexidronam in combination with docetaxel in patients with castrate metastatic prostate cancer.

The principal objective of this trial is to evaluate the safety, feasibility, and anti-tumor effects of a novel bone-targeted regimen consisting of Samarium Sm-153 lexidronam combined with docetaxel and prednisone. This present study design permits evaluation of the clinical activity of combining two distinct agents that have shown benefit for the treatment of patients with advanced androgen-independent prostate cancer and bone metastases. It enables assessment of potential synergistic interactions between a cytotoxic chemotherapy agent and a bone-targeting radioisotope agent in the setting of a bone-targeted therapy.

Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Prostatic Neoplasms
Drug: Samarium Sm-153 lexidronam + Docetaxel
1 mCi/kg Sm153 + 75 mg/m2 docetaxel
Other Name: Samarium Sm-153 lexidronam + Docetaxel
1
Intervention: Drug: Samarium Sm-153 lexidronam + Docetaxel
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
69
June 2008
Not Provided

Inclusion Criteria:

  • Have histological evidence of adenocarcinoma of the prostate.
  • Have progressive castrate metastatic disease.
  • Castrate levels of testosterone (<50 ng/ml). Treatment to maintain castrate levels of testosterone must be continued.
  • Must have evidence of at least 3 bone metastases on bone scan.
  • Patients for whom initial hormone treatment (exclusive of neoadjuvant hormone therapy) was a combined androgen blockade approach, must show progression of disease following withdrawal of the anti-androgen prior to enrollment.
  • Patients undergoing prior bisphosphonate treatments are eligible.
  • Patients who have received one prior treatment with 153Sm lexidronam or 89Sr are eligible provided it is at least 12 weeks from treatment with 153Sm lexidronam or 24 weeks from treatment with 89Sr.
  • Life expectancy of at least 12 weeks (based on co-morbidity).
  • KPS>60.
  • Lab requirements:

    • White Blood Count (WBC) ≥ 3,000/mm3;
    • Absolute Neutrophil Count (ANC) ≥ 1,500/ mm3;
    • Platelet (PLT) ≥ 100,000/mm3;
    • Hemoglobin (HGB) ≥ 10 mg/dl;
    • Bilirubin ≤ 2.0 mg/dl;
    • ALT/AST≤ 3 times the upper limit of normal;
    • Serum creatinine ≤ 2.0 mg/dl.
  • Patients must sign an informed consent.

Exclusion Criteria:

  • Patients with small cell carcinoma.
  • Patients with predominant visceral metastases (>3 lung or liver lesions) or symptomatic lymphadenopathy (scrotal or pedal edema).
  • Patients who have received more than one course of external beam radiation therapy directed at bone lesions.
  • Clinically significant cardiac disease (New York Heart Association Class III/IV).
  • History of other malignancies (other than non-melanoma skin cancer), unless in complete remission or off therapy for that disease for at least five years.
  • Have or are participating in a research study protocol or clinical trial protocol within 30 days of the date of the baseline visit.
Male
Not Provided
No
Contact: Colleen Gramkowski 800-833-3533 ext 8219 cgramkowski@cytogen.com
Contact: Melanie Giles 800-833-3533 ext 8112 mgiles@cytogen.com
United States
 
NCT00121095
424Sm32
No
Michael Manyak, MD, Cytogen Corporation
Cytogen Corporation
Not Provided
Principal Investigator: Michael J Morris, M.D. Memorial Sloan-Kettering Cancer Center
Cytogen Corporation
December 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP